Maze Therapeutics, Inc. 8-K

What Happened

• Maze Therapeutics, Inc. filed a Current Report on Form 8-K on March 25, 2026 announcing (1) its financial results for the fourth quarter and year ended December 31, 2025 (press release furnished as Exhibit 99.1), (2) topline Phase 2 clinical trial data for MZE829 in APOL1‑mediated kidney disease (press release furnished as Exhibit 99.2), and (3) the Board’s appointment of Dr. Neil Kumar as a Class I (non‑employee) director effective March 27, 2026.

Key Details

• The earnings and operational results were disclosed via a press release dated March 25, 2026 (Exhibit 99.1) covering Q4 and full-year 2025 results.
• Topline Phase 2 MZE829 data were announced in a separate March 25, 2026 press release (Exhibit 99.2); the 8‑K furnishes the press release but does not include additional data beyond the topline announcement.
• Dr. Neil Kumar (co‑founder & CEO of BridgeBio Pharma) was appointed to the Board effective March 27, 2026. Compensation: a pro rata portion of the $40,000 annual non‑employee director retainer and an option to purchase the lesser of 36,000 shares or an option sized to a grant‑date fair value of $750,000, vesting 1/36th monthly subject to continued service.
• The filing states there are no family relationships or related‑party transactions requiring disclosure between Dr. Kumar and Maze.

Why It Matters

• For investors, the 8‑K provides the company’s most recent quarterly and full‑year financial disclosure (useful for assessing recent revenue, expenses and cash position once the press release details are reviewed).
• The topline Phase 2 announcement is a clinical milestone for MZE829 in APOL1‑mediated kidney disease; topline results can materially affect the stock depending on efficacy and safety specifics disclosed in the press release.
• Adding Dr. Neil Kumar, an experienced biotech executive, to the board may strengthen governance and industry expertise at Maze; his compensation is standard for a non‑employee director and was disclosed in the filing.